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Abstract
The primary cilium is considered as a key component of morphological cellular stabil-
ity. However, cancer cells are notorious for lacking primary cilia in most cases, de-
pending upon the tumour type. Previous reports have shown the effect of starvation 
and cytostatics on ciliogenesis in normal and cancer cells although with limited suc-
cess, especially when concerning the latter. In this study, we evaluated the presence 
and frequency of primary cilia in breast fibroblasts and in triple‐negative breast can-
cer cells after treatment with cytostatics finding that, in the case of breast fibro-
blasts, primary cilia were detected at their highest incidence 72 hours after treatment 
with 120 nM doxorubicin. Further, multiciliated cells were also detected after treat-
ment with 80 nM doxorubicin. On the other hand, treatment with taxol increased the 
number of ciliated cells only at low concentrations (1.25 and 3.25 nM) and did not 
induce multiciliation. Interestingly, triple‐negative breast cancer cells did not present 
primary cilia after treatment with either doxorubicin or taxol. This is the first study 
reporting the presence of multiple primary cilia in breast fibroblasts induced by doxo-
rubicin. However, the null effect of these cytostatics on primary cilia incidence in the 
evaluated triple negative breast carcinomas cell lines requires further research.
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1  | INTRODUCTION
Primary cilium, an organelle found on nearly every cell in the human 
body, typically serves as a mechanical sensory tool; further, it is 
also involved in cell proliferation and embryonic development. This 
organelle is dynamically regulated during the cell cycle, appearing 
during the G0/G1 phases and resorbed prior to mitosis.1 The exact 
solubilization moment of primary cilia is determined by cell type and 
the expression of genes affecting resorption, such as Aurora A, Plk1 
and TcTex‐1.2,3 Usually, a cell has only one primary cilium which, as 
previously mentioned, is involved in morphogenesis, cell prolifera-
tion and differentiation signalling.4,5 Should there be a multiplication 
of centrosomes, a higher number of primary cilia will appear on the 
surface of cells as well, often bearing the same length and construc-
tion design, and spawning from the same ciliary pocket; however, 
the presence of multiple cilia has been mostly recorded in solid tu-
mours6,7 after exposure to ionizing irradiation8,9 or in ciliopathies.10 
Typically, primary cilia are always observed in myoepithelial cells 
and fibroblasts and with low incidence in luminal epithelium cells. 
Regarding cancer cells, a study of 26 breast cancer biopsy samples 
revealed the presence of primary cilia only on exceptional cases, es-
pecially in epithelial cells.11
Basal subtype B tumours, a classification of triple negative breast 
carcinomas (TNBCs), are characterized by the absence of oestrogen, 
progesterone and Her2/neu receptors,12 as well as by the rare pres-
ence of primary cilia. Among breast cancer tumours, TNBC has an 
estimated incidence of 10%‐20%, although from a histological point 
of view TNBCs are little differentiated and are often included in 
basal‐like subgroups. From a clinical standpoint, these tumours are 
frequently resistant to treatment, have quick progression, low 5‐year 
survival rate, increased local recurrence and are highly metastatic. 
This kind of tumours can be observed at any age; however, they 
mostly occur accompanied by BRCA1 mutations in younger women 
(>40 years of age).13 Chemotherapy is the treatment of choice for 
triple‐negative breast cancer patients, of which Doxorubicin and 
Taxol are the standard chemotherapeutic agents used as anticancer 
therapy in combination with α‐HER2/neu receptor targeted therapy. 
Doxorubicin belongs to the anthracyclines group, whereas Taxol 
is considered as a taxane. The former is an effective intercalating 
cytotoxic agent used in the treatment of various tumour types and 
commonly used in combination with the latter in adjuvant and neo-
adjuvant therapeutic strategies for breast cancer patients.14
Previous research on the effect of cytostatics on primary cilia 
has focused in the effects of Taxol over the elongation and shorten-
ing of primary cilia. In a study by Sharma et al., Taxol was shown to 
block the emergence of primary cilia in mammalian cell cultures.15 
However, low concentrations result in an increased quantity of free 
tubulin subunits in the cytosol, leading to enlarged primary cilia.16,17 
Ongoing research highlights two important questions in the cell biol-
ogy of cancer and primary cilia: (a) the significance of having primary 
cilia in normal cells and (b) the loss of primary cilia in cancer cells and 
its relation to drug resistance.18 Therefore, the increased primary 
cilia frequency induced by cytostatics could be used in other studies 
trying to assess the toxicity of these drugs.
2  | MATERIALS AND METHODS
2.1 | Cell culture
Unless otherwise stated, all standard chemicals and antibodies 
were purchased from Sigma‐Aldrich, Czech Republic. In this study, 
TNBC cell lines BT‐549 (ATCC, USA) and MDA‐MB‐231 were used 
(kindly supplied by Mgr. Jaroslav Truksa, Ph.D., Laboratory of Tumor 
Resistance, Institute of Biotechnology CAS, Prague), as well as skin 
fibroblasts. BT‐549 cells were cultured in DMEM 10% FBS (PAA, 
USA), 2% glutamine (Gibco, UK), 1% penicillin/streptomycin (Gibco, 
UK), 0.023 IU/mL insulin and incubated in a 5% CO2 atmosphere at 
37°C. MDA‐MB‐231 and fibroblasts were cultured in DMEM, 10% 
FBS (PAA, USA), 2% glutamine (Gibco, UK), 1% penicillin/strepto-
mycin (Gibco, UK) and incubated in a 5% CO2 atmosphere at 37°C. 
All cell lines were used until 10th to 12th passage and medium was 
replaced every 2 days for all experiments.
2.2 | Skin fibroblasts
Human fibroblasts were isolated from skin biopsies obtained in ac-
cordance and approved by the Ethics Committee of the University 
Hospital Hradec Kralove, Czech Republic and the European 
Ethics committee under the directive approved on 10 July 2014 
(Reference/license number: 201407 S12P). Donor patients signed 
an informed consent allowing us to work with the obtained sam-
ples. To isolate the fibroblasts, skin biopsies were kept in a basic 
solution (30 mL/2 g of tissue) after surgery and transported to 
the laboratory, where the biopsies were washed in PBS and the 
subcutaneous tissue was removed. Each individual tissue sample 
was incubated in 5 mL of a 2 U/mL dispase solution (Gibco, UK) 
for 18 hours at 4°C. After incubation, the samples were washed 
three times in PBS at room temperature (22°C). The dermis was 
separated from the epidermis using tweezers, washed in PBS and 
cut into small sections (<5 mm2). Then, the tissue was incubated in 
10 mL of digestion solution (1 g tissue/10 mL) in a rotating incuba-
tor at 37°C/6 g. After 4 hours, the samples were filtered through 
a 40 μm strainer into a new sterile 50 mL tube. The cell number 
was determined from this suspension and centrifuged for 10 min-
utes/150 g. The supernatant was decanted and the cell pellet 
was resuspended in culture media, plated in a T‐75 flask (1 × 105 
cells per flask) and incubated in a 5% CO2 atmosphere at 37°C for 
14 days.
2.3 | Cytostatic drugs
Doxorubicin and Taxol were dissolved in 0.5% DMSO and kept in 
1 mM stock solutions. Doxorubicin and Taxol were diluted in culture 
media before use at a ratio of 1:100 and 1:1000 respectively.
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2.4 | Cell treatment and immunofluorescence
MDA‐MB‐231, BT‐549 and fibroblasts cells were cultured in 6‐well plates 
at a density of 3 × 105 cells per well and incubated at 37°C/5% CO2 for 
24 hours, each well contained a gelatine‐coated coverslip. After this pe-
riod, the cells were treated with Doxorubicin (10, 20, 40, 80, and 120 nM) 
or Taxol (1.25, 3.25, 5.25, 6.25 and 12.5 nM) for 72 hours. Control cells 
were kept under the same conditions in culture media with or without 
DMSO (0.5%). After treatment, the cells were fixed with 4% paraform-
aldehyde for 10 minutes at room temperature and washed three times 
with PBS. Immunostaining was performed as follows: cells were blocked 
with goat serum (Jackson Immunoresearch, USA) 1:20 for 30 minutes; 
anti‐acetylated tubulin 1:800 for 1 hour; anti‐gamma tubulin 1:500 for 
1 hour; Cy3‐conjugated donkey anti‐mouse secondary antibody 1:300 
for 45 minutes in the dark; Alexa 488 conjugated donkey anti‐rabbit sec-
ondary antibody (JacksonImmunoresearch, USA) 1:300 for 45 minutes 
in the dark. Imaging analysis was performed with a Nikon Eclipse fluores-
cence microscope (Prague, Czech Republic) observed with an oil‐immer-
sion 60× objective. All experiments were performed in triplicate.
2.5 | Cytotoxicity test
A WST‐1 test (Roche; Basel, Switzerland) was used to determine 
cell viability after treatment with Doxorubicin (10, 20, 40, 80, and 
120 nM) or Taxol (1.25, 3.25, 5.25, 6.25 and 12.5 nM). All cell lines 
were plated and treated in a 96‐well‐plate (1 × 103 cells per well), 
and incubated at 37°C/5% CO2 for 24 hours. After 72 hours, 10 µL 
of WST‐1 reagent was added and incubated for 3 hours at 37°C/5% 
CO2 and analysed in a Tecan SpectraFluor Plus spectrometer (Tecan 
Austria GmbH; Grödig, Austria) at a wavelength of 440 nm. All ex-
periments were performed in triplicate.
2.6 | Transmission electron microscopy (TEM)
Fibroblasts were fixed in 3% glutaraldehyde (in 0.1 M cacodylate 
buffer, pH 7.2) for 5 minutes at 37°C and then for 3 hours at room tem-
perature, washed in cacodylate buffer (0.1 M, pH 7.2) and post‐fixed 
in 1% OsO4 (in 0.1 M cacodylate buffer, pH 7.2) for 1 hour at room 
temperature. After rinsing in cacodylate buffer (0.1 M, pH 7.2), the 
cells were dehydrated in graded alcohols (50%, 75%, 96% and 100%), 
cleared in propylene oxide and embedded in a mixture of Epon 812 
and Durcupan (Sigma; polymerization for 3 days at 60°C). Semi‐thin 
sections were stained with toluidine blue. Ultra‐thin sections were 
cut on an Ultrotome Nova (LKB, Sweden), mounted into formvar car-
bon‐coated copper grids, counterstained with uranyl acetate and lead 
citrate and examined in a JEOL JEM‐1400Plus transmission electron 
microscope (at 120 kV JEOL, Japan). Images were captured with inte-
grated 8Mpix CCD camera and software (JEOL, Japan).
2.7 | Statistical analysis
Graphs were made using the GraphPad Prism 6 biostatistics soft-
ware (GraphPad Software, USA). The statistical analysis between 
the evaluated groups was performed with one‐way ANOVA fol-
lowed by a post‐hoc Tukey test (P < 0.05).
3  | RESULTS
3.1 | Proliferation and viability of BT‐549, MDA‐
MB‐231 and fibroblasts after treatment with 
Doxorubicin and Taxol
Cytostatics are known inhibitors of cell viability and proliferation; 
therefore we had to determine a suitable concentration in which 
the cells would stop proliferating without losing viability. To achieve 
this purpose, the MDA‐MB‐231, BT‐549 and fibroblast cells were 
maintained with Doxorubicin or Taxol at various concentrations (10, 
20, 40, 80 and 120 nM and 1.25, 3.25, 5.25, 6.25 and 12.5 nM re-
spectively), followed by a WST‐1 test after 72 hours of treatment. 
The number of living cells was significantly lower after Doxorubicin 
(Figure 1A‐C) and Taxol (Figure 1D‐F) treatment across all cell lines.
3.2 | Primary cilia incidence and multiciliation 
induced by the cytostatics Doxorubicin and Taxol
Regarding Doxorubicin, the number of fibroblasts with primary 
cilia increased to ~70%, in comparison with control untreated cells, 
after 72 hours of treatment with various concentrations of this cy-
tostatic (10, 20, 40, 80 and 120 nM), observing a higher incidence 
after treatment with 120 nM Doxorubicin. Overall, this effect 
could be observed evenly across the entire dose range used in this 
study (Figure 2A). After 72 hours of treatment, primary cilia were 
detected by immunostaining (Figure 2B – control cells; Figure 2C 
– 120 nM Doxorubicin) and electron microscopy (Figure 2D – con-
trol; Figure 2E – 120 nM Doxorubicin). Interestingly, ~20%‐40% 
of fibroblasts treated with 20‐120 nM Doxorubicin showed two 
or more cilia after 72 hours of treatment, observing a higher num-
ber of multiciliated cells at a dose of 80 nM Doxorubicin (~40%; 
Figure 3A). However, no multiciliated cells could be observed 
after treatment with 10 nM Doxorubicin or in untreated cells 
(Figure 3A). Multiple primary cilia were detected by immunostain-
ing (Figure 3B) and electron microscopy (Figure 3C) after 72 hours 
of treatment.
Concerning Taxol, the treatment of fibroblasts with various 
concentrations (1.25, 3.25, 5.25, 6.25 and 12.5 nM) for 72 hours 
revealed a significantly higher incidence of primary cilia after 
treatment with 1.25 and 3.25 nM Taxol (~80%) (Figure 4A), as 
detected by immunostaining (Figure 4B) and electron microscopy 
(Figure 4C). However, this incidence rate was slightly decreased 
in the cells within the higher concentration range (5.25, 6.25, and 
12.5 nM), although without change when compared to the un-
treated cells.
Interestingly, a complete absence of primary cilia was noted in 
MDA‐MB‐231 cells after treatment with either Doxorubicin (10, 20, 
40, 80, and 120 nM) or Taxol (1.25, 3.25, 5.25, 6.25 and 12.5 nM) 
for 72 hours, an effect that was repeated in BT‐549 cells (Figure 5).
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4  | DISCUSSION
In this work, we sought to determine the effect that the cytostat-
ics Doxorubicin and Taxol could have on primary cilia incidence in 
triple‐negative breast cancer cells. We chose these cytostatics be-
cause they are commonly used in the treatment of breast cancer. 
On one hand, Doxorubicin (DOX) acts by intercalating into the DNA 
strands inhibiting topoisomerase II activity and thus inducing strand 
breaks when DNA is being replicated; in addition, it also promotes 
the formation of reactive oxygen species (ROS), which are highly 
toxic. Taxol, on the other hand, inhibits microtubule depolymerisa-
tion,19 resulting in shorter primary cilia and affecting their frequency 
in the exposed cells15; therefore, it was included as a negative‐con-
trol drug in our experiments.
Solid tumours possess a characteristic absence or low incidence 
of primary cilia which, when present, may also have a compromised 
structure and function. However, some tumour types that are de-
pendent upon the Hedgehog (Hh) signalling pathway often have an 
increased frequency of primary cilia.20,21 Further, several types of 
tumours have been associated with altered Hh, Wnt, NOTCH and 
Hippo signalling pathways, which are related to primary cilia; there-
fore, compromised signal transduction could also be caused by de-
fects in the formation, structure or function of primary cilia.22
Primary cilia normally occur in approximately 70% of fibroblasts 
and from 7% to 19% of epithelial cells from healthy breast tissue.11 
However, the study of 11 breast cancer cell lines revealed that pri-
mary cilia were only present in four of these and at the very low 
frequency of 0.3%‐4%; curiously, these cell lines had the shared 
characteristic of being basal B subtypes, which are analogous to 
triple‐negative breast cancer cells.11 Regardless, primary cilia have 
been found in some cases of TNBCs, which hints at the existence of 
several TNBC subtypes in which the reason for this exclusive pres-
ence of primary cilia is yet unclear. A possible explanation could be 
that these tumour subtypes are dependent upon the Hh signalling 
pathway and hence upon primary cilia, as it has been observed in 
most basal cell carcinomas and medulloblastomas.22
In this study, the chemosensitive triple‐negative breast cancer 
cell lines BT‐549 and MDA‐MB‐231 were used, in addition to normal 
skin fibroblasts as a comparative control, to test the effect that these 
cytostatics could have on primary cilia incidence. The cell lines were 
treated with 10, 20, 40, 80 and 120 nM Doxorubicin and 1.25, 3.25, 
5.25, 6.25 and 12.5 nM Taxol for 72 hours to determine the dose in 
which the cells would become affected by the cytostatic drug with-
out compromising viability or inducing cell death. Accordingly, the 
number of viable cells decreased with an increased concentration 
of cytostatics.
Regarding Taxol, the included cell lines showed consistently de-
creasing proliferation and viability as the dosage of Taxol increased; 
therefore, low doses of 1.25, 3.25, 6.25 and 12.5 nM Taxol were 
chosen based on previous experiments.23
In our study, fibroblasts were treated with the mentioned dose 
range of Doxorubicin and Taxol to establish their baseline effect 
on ciliogenesis. Concerning Doxorubicin, an even increment in pri-
mary cilia frequency was observed across the full dose range (10, 
20, 40, 80 and 120 nM) after 72 hours of treatment, reaching a 
maximum value of 70% after under a 120 nM dose. Interestingly, 
F I G U R E  1   WST‐1 test after 72 h of treatment with Doxorubicin (10, 20, 40, 80 and 120 nM) in BT‐549 (A), MDA‐MB‐231 (B), and 
fibroblasts (C). WST‐1 test after 72 h of treatment with Taxol (1.25, 3.25, 5.25, 6.25 and 12.5 nM) in BT‐549 (D), MDA‐MB‐231 (E), and 
fibroblasts (F) (60×). *P < 0.05, **P < 0.01, ***P < 0.001 vs control group
5732  |     FILIPOVÁ et aL.
20% to 40% of fibroblasts showed two or more cilia after treat-
ment with doses of 20‐120 nM, reaching the maximum value of 
40% multiciliated cells after treatment with 80 nM. It must be 
mentioned that multiciliated cells were also in possession of mul-
tiple centrosomes, an effect that has also been observed in some 
tumour cells after exposure to cytostatics or ionizing radiation.7,9 
The treatment with Taxol also resulted in increased primary cilia 
frequency, reaching a value of 80% after 72 hours of treatment 
with 1.25 and 3.25 nM; however, the exposure to higher doses 
(5.25, 6.25, and 12.5 nM) resulted in a slightly decreased primary 
cilia frequency in the treated fibroblasts when compared to the 
lower dose range (1.25 and 3.25 nM) but not when compared 
against the untreated control. It must be highlighted that, unlike 
the treatment with Doxorubicin, the treatment with Taxol did not 
result in multiciliated cells.
Once the baseline effect of Doxorubicin and Taxol was de-
termined on healthy cells, we proceeded to test their effect on 
primary cilia frequency in the triple‐negative breast cancer cell 
lines MDA‐MB‐231 and BT‐549. Unlike fibroblasts, however, the 
treatment of these cells with either Doxorubicin (10, 20, 40, 80 
and 120 nM) or Taxol (1.25, 3.25, 5.25, 6.25 and 12.5 nM) did 
not increase the frequency of primary cilia, which was somewhat 
intriguing.
Based on previous results we were aware that primary cilia are 
absent or in very low percentage in the triple‐negative breast cancer 
cell lines BT‐549 and MDA‐MB‐231.11,24,25 This absence of primary 
cilia has been associated with a loss of function mutation in the tu-
mour suppressor gene p53.26 However, the effect that Doxorubicin 
could have on primary cilia frequency in these cell lines has been 
heretofore unreported.
F I G U R E  2   A, Shows the percentage ciliated fibroblasts after treatment with various concentrations of Doxorubicin (10, 20, 40, 80 and 
120 nM). B, Control cells with primary cilia were observed after 72 h of culture. C, Primary cilia were observed 72 h after treatment with 
120 nM Doxorubicin. Representative immunofluorescence images of primary cilia: acetylated tubulin (red, axoneme), gamma‐tubulin (green, 
basal body), nuclei (blue). D, Longitudinal section of a primary cilium (arrow) in fibroblast control cells. The cilium emerges from a basal body 
(open arrows). The proximal region of the cilium is situated within an invagination of the plasma membrane, a ciliary pocket (arrowheads). n, 
nucleus (Bar 500 nm). E, Transverse section of a primary cilium in fibroblasts after treatment with 40 nM Doxorubicin, showing the structure 
of its axoneme (arrows): nine microtubule doublets arranged at the periphery, an undeveloped central microtubule doublet. Outer plasma 
membrane of the ciliary pocket surrounding the cilium shaft (arrowheads). n, nucleus (Bar 200 nm). *P < 0.05, **P < 0.01 vs control group 
(60×)
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A particular issue in this regard is that multiple primary cilia 
are associated with an abnormal number of centrosomes in the 
cell and, according to other unpublished results from our group, 
it appears that this is a relevant issue in understanding the rela-
tion between ciliogenesis and carcinogenesis. Elaborating in this 
regard, several tumours and some ciliopathies6,7,10 possess a char-
acteristic and aberrant number of centrosomes. Multiple centro-
somes occur in tumour cells in which mutations of the p53, BRCA1 
and BRCA2 genes are present.27-29 Often, the surface of cells with 
multiple centrosomes displays an increased number of primary 
cilia (2‐6) with the same structure and similar length. Curiously, 
the total number of Smo receptors, serotonin type 6 receptors, fi-
brocystin protein and Arl13b protein (ADP‐ribosylation factor‐like 
protein 13b) present on these multiple cilia remains the same as in 
single primary cilia. This suggests that since this number remains 
the same regardless of the number of cilia, the receptor and pro-
tein content along the total length of the primary cilia is greater, 
meaning that the amount of these proteins per unit of length in 
the primary cilia is smaller in multiciliated cases, thus resulting in a 
lower receptor density. Such dilution in receptor density can lead 
to weaker signalling stimuli,30 which have been observed in the 
alternative Wnt signalling pathways of cells with two or more pri-
mary cilia.31
Primary cilia play an important role in cell growth and tissue ho-
meostasis and, in normal cells, the development of primary cilia is 
a dynamic process whose formation can occur in either G0/G1 or, 
more commonly, during the S/G2 phases; however, and almost with-
out exception, the cilium is absorbed before entering mitosis and 
reappears once again in post‐cytokinetic phases of the cell cycle. 
This periodic cilium absorption is therefore related to the cell cycle 
and affects cell sensitivity to external signals associated with cilia 
receptors.32 TNBC cells, however, are notorious for their lack of pri-
mary cilia, although they can sometimes occur with extremely low 
frequency.33 Regardless, this low‐primary cilium frequency cannot 
be increased under serum starvation conditions in TNBC cells, which 
has been a proven method in healthy cells.11
Our study reports the null effect of Doxorubicin or Taxol on the 
incidence of primary cilia in triple‐negative breast cancer cell lines 
F I G U R E  3   A, Shows the percentage of multiciliated fibroblasts after treatment with various concentrations of Doxorubicin (10, 20, 40, 
80 and 120 nM). B, Multiple cilia were observed 72 h after treatment with 80 nM Doxorubicin. Representative immunofluorescence images 
of primary cilia: acetylated tubulin (red, axoneme), gamma‐tubulin (green, basal body), nuclei (blue). C, Transverse section of multiple cilia 
in fibroblasts after treatment with 80 nM of Doxorubicin reveals the structure of its axoneme (arrows). The outer plasma membrane of the 
ciliary pocket surrounds the cilium shaft (arrowheads). n, nucleus (Bar 1.5 nm). ***P < 0.001 vs control group. Magnification (60×)
5734  |     FILIPOVÁ et aL.
F I G U R E  4   A, Shows the percentage of cells with primary cilia in fibroblasts after treatment with various concentrations of Taxol 
(1.25, 3.25, 5.25, 6.25 and 12.5 nM). B, Primary cilia were observed after 72 h of treatment with 1.25 nM Taxol. Representative 
immunofluorescence images of primary cilia: acetylated tubulin (red, axoneme), gamma‐tubulin (green, basal body), nuclei (blue). C, TEM 
image of fibroblasts after treatment with 1.25 nM Taxol shows the transverse section of a primary cilium (arrow), it contains six microtubule 
doublets arranged at the periphery and one centrally located microtubule doublet. The open arrows depict the outer plasma membrane of 
the ciliary pocket surrounding the cilium shaft (Bar 0.25 nm) (60×). ***P < 0.001 vs control group
F I G U R E  5   Representative 
immunofluorescence images of BT‐549 
and MDA‐MB‐231 cells: acetylated 
tubulin (red), nuclei (blue). Primary cilia 
are absent after 72 h of treatment with 
Doxorubicin and Taxol in BT‐549 and 
MDA‐MB‐231 (60×)
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BT‐549 and MDA‐MB‐231. Previous reports had only addressed 
the use of taxanes and their effect on ciliary length in breast cancer 
cell lines but not of Doxorubicin, which has not been reported else-
where. Further, we also report the presence of multiple primary cilia 
in breast fibroblasts induced by Doxorubicin which, to the best of 
our knowledge, is now reported for the first time. The null effect of 
these cytostatics on primary cilia incidence in the evaluated TNBC 
cell lines, as opposed to their effect on healthy cells, hints at some 
larger mechanism at play that could be involved with the inherent 
characteristics of malignant cells; however, these considerations 
must be addressed further and more in depth before an accurate 
conclusion can be reached.
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